株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カテーテル関連血流感染症(CRBSI)- 疫学予測 2028年

Catheter-Related Bloodstream Infections (CRBSIs) - Epidemiology Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 909902
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.60円で換算しております。
Back to Top
カテーテル関連血流感染症(CRBSI)- 疫学予測 2028年 Catheter-Related Bloodstream Infections (CRBSIs) - Epidemiology Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 100 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、スペイン、イタリア、日本)のカテーテル関連血流感染症(CRBSI)の罹患数は、2017年に66万7,753人と推計され、2028年にかけてその数は増加すると予測されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、スペイン、イタリア、日本)のカテーテル関連血流感染症(CRBSI)の疫学について調査し、疾患の概要、国別の罹患数および診断数の推移と予測などについてまとめています。

目次

第1章 重要洞察

第2章 カテーテル関連血流感染症(CRBSI):疫学概要

  • 分布状況(実績値)
  • 分布状況(予測値)

第3章 カテーテル関連血流感染症(CRBSI):疾患背景と概要

  • イントロダクション
  • 中心ライン関連血流感染症(CLABSI)とカテーテル関連血流感染症(CRBSI)の違い
  • カテーテル関連血流感染症(CRBSI)の原因
    • 微生物
    • 血管内デバイス
  • カテーテル関連血流感染症(CRBSI)の危険因子
  • カテーテル関連血流感染症(CRBSI)の病因
  • カテーテル関連血流感染症(CRBSI)の診断
  • カテーテル関連血流感染症(CRBSI)の診断ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の総罹患数
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の診断数
  • 主要7カ国のカテーテル関連血流感染症(CRBSI)の診断数:起炎菌別
  • キーオピニオンリーダーの意見

第5章 米国の疫学

  • 仮定と根拠
  • 総罹患数
  • 総診断数
  • 診断数:起炎菌別

第6章 欧州5カ国の疫学

  • ドイツの疫学
    • 仮定と根拠
    • 総罹患数
    • 総診断数
    • 診断数:起炎菌別
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学

第7章 日本の疫学

  • 仮定と根拠
  • 総罹患数
  • 総診断数
  • 診断数:起炎菌別

第8章 付録

  • 調査方法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

図表

List of Tables

  • TABLE 1: TERMINOLOGY: CLABSI OR CRBSI
  • TABLE 2: VARIOUS RISK FACTORS OF CRBSI
  • TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017-2028)
  • TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017-2028)
  • TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017-2028)
  • TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017-2028)
  • TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017-2028)
  • TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017-2028)
  • TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017-2028)
  • TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017-2028)
  • TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017-2028)
  • TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017-2028)
  • TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017-2028)
  • TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017-2028)
  • TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017-2028)
  • TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017-2028)
  • TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017-2028)
  • TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017-2028)
  • TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017-2028)
  • TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017-2028)
  • TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017-2028)
  • TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017-2028)
  • TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017-2028)
  • TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017-2028)
  • TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017-2028)
  • TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017-2028)

List of Figures

  • Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion
  • Figure 2: Important pathogenic determinants of catheter-related infections
  • Figure 3: Potential sources of infection of a percutaneous intravascular device
  • Figure 4: Total Incident Population of CRBSI in the 7MM (2017-2028)
  • Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017-2028)
  • Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017-2028)
  • Figure 7: Total Incident Population of CRBSI in the US (2017-2028)
  • Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017-2028)
  • Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017-2028)
  • Figure 10: Total Incident Population of CRBSI in Germany (2017-2028)
  • Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017-2028)
  • Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017-2028)
  • Figure 13: Total Incident Population of CRBSI in France (2017-2028)
  • Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017-2028)
  • Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017-2028)
  • Figure 16: Total Incident Population of CRBSI in Italy (2017-2028)
  • Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017-2028)
  • Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017-2028)
  • Figure 19: Total Incident Population of CRBSI in Spain (2017-2028)
  • Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017-2028)
  • Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017-2028)
  • Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017-2028)
  • Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017-2028)
  • Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017-2028)
  • Figure 25: Total Incident Population of CRBSI in Japan (2017-2028)
  • Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017-2028)
  • Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017-2028)
目次
Product Code: DIEI0375

DelveInsight's ‘Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of CRBSI in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028.

Disease Understanding:

CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. It is also known as catheter-related sepsis.

In the current scenario, there is no US Food and Drug Administration (FDA) approved drugs/lock solution present in the market, specifically for this indication, and therefore, the availability of new therapies will be the major market driver for the therapeutic market of CRBSI. Only one emerging therapy is present, which is in pipeline, i.e. Mino-Lok Therapy by Citius Pharmaceuticals. Due to non-competitiveness and poor pipeline, the launch of Mino-lok in the US or EU will create a huge hype and will have the only candidate in the CRBSI therapeutic landscape. The treatment of CRBSI is mainly preventive and is done by using off-label antibiotics. So, the need for a potential drug candidate is necessary and urgent.

Epidemiology:

The CRBSI epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CRBSI in the 7MM, Total Diagnosed Incident Population of CRBSI in the 7MM, and Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM] scenario of CRBSI in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2028.

As per DelveInsight's analysis, total Incident Population of Catheter-Related Bloodstream Infection (CRBSI in the 7MM was found to be 667,753 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the European 5 countries, Germany had the highest incident population of CRBSI followed by France and United Kingdom. On the other hand, Spain had the lowest incident population of CRBSI.

Another estimate of Delveinsight's analysis shows that most of the incident cases of CRBSI are confirmed with specific bacterial species. The estimates show that Gram-positive bacteria are implicated in the majority of the cases of CRBSI in comparison with Gram-negative bacteria.

Report Scope:

  • The report covers detailed overview of Catheter-related Bloodstream Infections explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Catheter-related Bloodstream Infections
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of Catheter-related Bloodstream Infections in the 7MM

Key Strengths:

  • 10 Year Forecast of Catheter-related Bloodstream Infections epidemiology
  • 7MM Coverage
  • Total Incident Population of CRBSI
  • Total Diagnosed Incident Population of CRBSI
  • Diagnosed Incidence of CRBSI by Causative Pathogens

Report Assessment:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Catheter-Related Blood Stream Infection (CRBSI) Epidemiology Overview at a Glance

  • 2.1. Total Epidemiology Distribution of CRBSI in 2017
  • 2.2. Total Epidemiology Distribution of CRBSI in 2028

3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Difference between CLABSI and CRBSI
  • 3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
    • 3.3.1. Micro-organisms
    • 3.3.2. Intravascular Devices
  • 3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
  • 3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
  • 3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
  • 3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
    • 3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
    • 3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
    • 3.7.3. British Intestinal Failure Alliance (BIFA):
    • 3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Incident Population of CRBSI in the 7MM
  • 4.3. Total Diagnosed Incident Population of CRBSI in the 7MM
  • 4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM
  • 4.5. Some KOL Insights

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Incident Population of CRBSI in the United States
  • 5.3. Total Diagnosed Incident Population of CRBSI in the United States
  • 5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Incident Population of CRBSI in Germany
    • 6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
    • 6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Incident Population of CRBSI in France
    • 6.2.3. Total Diagnosed Incident Population of CRBSI in France
    • 6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Incident Population of CRBSI in Italy
    • 6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
    • 6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Incident Population of CRBSI in Spain
    • 6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
    • 6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Incident Population of CRBSI in the United Kingdom
    • 6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
    • 6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Incident Population of CRBSI in Japan
  • 7.3. Total Diagnosed Incident Population of CRBSI in Japan
  • 7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Back to Top